We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Positive Lymphocyte Gene Rearrangement Evaluated for Hematologic Malignancies

By LabMedica International staff writers
Posted on 08 Sep 2020
The diagnosis of a lymphoid malignancy requires the establishment of monoclonality of a lymphocyte population through morphologic assessment and laboratory testing, such as flow cytometry, immunohistochemistry, and cytogenetic analysis.

These methods can yield conflicting results, however, and in up to 15% of cases of suspected lymphoid malignancies, molecular assessment of immunoglobulin (IG) and/or T-cell receptor (TCR) gene rearrangements is necessary to confirm a diagnosis. More...
the presence of a population of B or T cells with the same gene rearrangement pattern is highly supportive of lymphoid malignancy.

Medical scientists at the Yale School of Medicine (New Haven, CT, USA) extracted data from medical records of patients who underwent IG or TCR gene rearrangement testing at an affiliated hospital from January 1, 2013 to July 6, 2018. Date of testing, specimen source, and morphologic, flow cytometric, immunohistochemical, and cytogenetic characterization of the tissue source were recorded. Gene rearrangement results were categorized as test positive/phenotype positive (T+/P+), test positive/phenotype negative (T+/P−), test negative/phenotype negative (T−/P−), or test negative/phenotype positive (T−/P+) based on comparison to other studies and/or final diagnosis. Patient records were reviewed for subsequent diagnosis of hematologic malignancy for patients with positive gene rearrangements, but no other evidence for a disease process.

The authors reported that a total of 136 patients with 203 gene rearrangement studies were analyzed. For TCR studies, there were two T+/P− and one T−/P+ results in 47 peripheral blood (PB) assays, as well as seven T+/P− and one T−/P+ results in 54 bone marrow assays. Regarding IG studies, three T+/P− and 12 T−/P+ results in 99 bone marrow (BM) studies were identified. None of the 12 patients with T+/P− TCR or IG gene rearrangement studies later developed a lymphoproliferative disorder.

The 12 T/Pþ IG studies included four cases of multiple myeloma (MM), three cases of monoclonal gammopathy of undetermined significance, one case of low-grade B-cell non-Hodgkin’s lymphoma, one case of monoclonal B-cell lymphocytosis, one case of low-grade B–non-Hodgkin’s lymphoma plus MM, one case of low-grade B–non-Hodgkin’s lymphoma plus myelodysplastic syndrome, and one case of monoclonal gammopathy of undetermined significance plus adult T-cell leukemia/lymphoma. The two T/Pþ TCR studied corresponded to one diagnosis of T-cell acute lymphoblastic leukemia and one diagnosis of T-cell large granular lymphocytic leukemia.

The authors concluded that the results from the present study suggest positive IG/TCR gene rearrangement studies are not predictive of lymphoproliferative disorders in the context of otherwise negative BM or PB findings. As such, when faced with equivocal pathology reports, clinicians can be practically advised that isolated positive IG/TCR gene rearrangement studies do not indicate a need for closer surveillance. The study was published on July 31, 2020 in the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Yale School of Medicine


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.